Page last updated: 2024-12-05
strospeside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
strospeside : A cardenolide glycoside in which the parent structure gitoxigenin is glycosylated at the 3beta-hydroxy group by beta-D-digitalose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21636336 |
| CHEBI ID | 70992 |
| MeSH ID | M0044389 |
Synonyms (26)
| Synonym |
|---|
| desgluco-digitalinum verum |
| strospesid |
| gitoxogenin-d-digitalosid |
| strospesid [german] |
| (3beta,5beta,16beta)-3-((6-deoxy-3-o-methyl-d-galactopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide |
| gitoxigenin 3-o-monodigitaloside |
| 5-beta-card-20(22)-enolide, 3-beta-((6-deoxy-3-o-methyl-d-galactopyranosyl)oxy)-14,16-dihydroxy- |
| einecs 209-859-8 |
| desgluco-digitalinum verum [german] |
| strospeside |
| gitoxogenin-d-digitalosid [german] |
| gitoxigenin 3-o-beta-d-digitalopyranoside |
| 3beta-(6-deoxy-3-o-methyl-beta-d-galactopyranosyloxy)-14,16beta-dihydroxy-5beta-card-20(22)-enolide |
| CHEBI:70992 |
| card-20(22)-enolide, 3-((6-deoxy-3-o-methyl-d-galactopyranosyl)oxy)-14,16-dihydroxy-, (3beta,5beta,16beta)- |
| (3beta,5beta,16beta)-3-[(6-deoxy-3-o-methyl-d-galactopyranosyl)oxy]-14,16-dihydroxycard-20(22)-enolide |
| Q27139236 |
| 3-[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-3-[(2r,3r,4s,5s,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14,16-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one |
| gitoxigenin 3-o-beta-d-digitaloside |
| unii-p5sq9u79a5 |
| 109279-30-3 |
| p5sq9u79a5 , |
| (3beta,5beta,16beta)-3-((6-deoxy-3-o-methyl-beta-d-galactopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide |
| (3.beta.,5.beta.,16.beta.)-3-((6-deoxy-3-o-methyl-.beta.-d-galactopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide |
| card-20(22)-enolide, 3-((6-deoxy-3-o-methyl-d-galactopyranosyl)oxy)-14,16-dihydroxy-, (3.beta.,5.beta.,16.beta.)- |
| gitoxigenin 3-o-.beta.-d-digitaloside |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| cardenolide glycoside | Any member of the class of cardenolides with glycosyl residues attached to position 3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||